NOVT in three months: buy, wait or sell?
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
- Buy / Wait / Sell rating
- 3-month target price
- Bear · Base · Bull
- vs. the market
What happened with NOVT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Novanta Inc. designs and manufactures products that help equipment makers control lasers and precise movement, automate tasks, and perform imaging and surgical procedures. Its customers are mainly original equipment manufacturers, or OEMs, which incorporate Novanta’s products into systems they sell to end users. Novanta sells most products directly through technical sales staff, with some sales through distributors and resellers.
Its two businesses contribute similar amounts of revenue. Automation Enabling Technologies supplies laser and motion-control products used in industrial processing, robotics and medical automation. Medical Solutions supplies technologies for medical equipment and operating rooms, including endoscopic pumps, related disposables and imaging products. This makes Novanta a supplier to both industrial and medical equipment makers, rather than solely a medical-device company.
Sales depend on OEM customers developing and selling systems that use Novanta’s products. Once those products are built into a customer’s system, changing suppliers is generally difficult until the system’s life cycle ends, especially in medical applications. Two medical-market OEM customers contribute a substantial combined share of revenue, but major customers have no obligation to buy minimum quantities. Novanta’s regulated medical devices generally need FDA clearance or approval to be marketed in the U.S., unless exempt, and must meet EU conformity requirements before EU sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Regal Rexnord competes with Novanta to supply precision motion-control products to factory-automation and medical equipment manufacturers. Its Automation & Motion Control business is the part to watch for developments in those products and customer markets.
Zebra Technologies overlaps with Novanta in products customers buy to identify items and capture images, including barcode imaging, radio-frequency identification (RFID) and machine vision. Watch Zebra's product developments in these areas, where its established end-user relationships and channel network support its competitive position.
CTS Corporation and Novanta share exposure to medical and industrial equipment makers' production and new-product launches: CTS sells sensors and components that create movement, while Novanta supplies motion, imaging and laser technologies. Watch CTS's medical and industrial sales rather than its total sales, which also include transportation and aerospace and defense.
Timken competes with Novanta for industrial automation equipment customers through its linear-motion and precision-drive products. Watch developments in those products rather than treating Timken's broader bearing business as a direct read-through to Novanta's precision-motion sales.
CTS Corporation earningsCTS
CTS Corporation's medical and industrial sales offer a read on whether equipment makers' production and new-product activity is supporting the OEM markets Novanta serves.
Read CTS Corporation's medical and industrial sales separately, rather than relying on its total, which also includes transportation and aerospace and defense. Strength in both would point to firmer production or new-product activity among equipment makers, a supportive backdrop for Novanta's medical and advanced-industrial customers; weakness in either would suggest that market is cooling, not that Novanta's own orders have necessarily fallen.
Regal Rexnord Corporation earningsRRX
Regal Rexnord Corporation's Automation & Motion Control business offers a read on factory-automation and medical-equipment makers' demand for precision-motion products and the competition Novanta faces.
Watch Regal Rexnord Corporation's Automation & Motion Control business, not its broader bearing business, as a read on Novanta's precision-motion sales. Stronger results could mean equipment makers are buying more overlapping products, or that Regal Rexnord is winning competitive programs; weaker results point to softer activity in that market, not necessarily to Novanta gaining share.
Novanta Inc. earningsThis company
Novanta's report will show whether medical-equipment OEM demand is translating into revenue and profit in Medical Solutions, alongside the performance of its automation business.
Read revenue and operating profit for Medical Solutions alongside the same measures for Automation Enabling Technologies. If medical revenue and profit rise together, OEM demand is turning into more profitable shipments; if revenue weakens or profit trails it, demand may be softer or costs and pricing may be squeezing profit. The automation results show whether any improvement is confined to medical customers or spans both markets.